NCT00639483 - Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia | Biotech Hunter

Enrollment

270

Participants

Timeline

Start Date

March 31, 2003

Study Completion Date

January 31, 2004

Conditions

Schizophrenia

Interventions

DRUG

Celecoxib

200 mg oral capsules twice daily as add-on therapy to risperidone twice daily (range 2-8 mg/day) for 11 weeks

DRUG

Placebo

Matched oral placebo as add-on to risperidone twice daily (range 2-8 mg/day) for 11 weeks

Trial Locations (17)

Pfizer Investigational Site, Mandaluyong

Pfizer Investigational Site, Lanús

Pfizer Investigational Site, La Plata

Pfizer Investigational Site, Bonn

Pfizer Investigational Site, München

Pfizer Investigational Site, München

Pfizer Investigational Site, La Plata

Pfizer Investigational Site, PR

Pfizer Investigational Site, Salvador

Pfizer Investigational Site, Aparecida de Goiânia

Pfizer Investigational Site, Rio de Janeiro

Pfizer Investigational Site, São Paulo

Pfizer Investigational Site, Münster

Pfizer Investigational Site, Pasig

Pfizer Investigational Site, Niao-Sung Hsiang

Pfizer Investigational Site, Taipei

Pfizer Investigational Site, Mexico City